XPhyto Therapeutics Corp.
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / January 17, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Drahoslav Zdarek as the Company's Head of Sales, Europe. Mr. Zdarek will focus on building out distribution, sales and marketing of the Company's products, with high priority on the commercialization of Covid-ID Lab, the Company's German CE Mark approved rapid RT-PCR test registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.
Mr. Zdarek has over 25 years of European pharmaceutical sales and marketing success. His previous positions include over 13 years of marketing and sales for Teva Pharmaceutical focusing on the European market, Head of Business Development at CC Pharma GmbH and Head of Sales at Cell Pharma GmbH, a subsidiary of Stada Arzneimittel AG. Mr. Zdarek is a licensed pharmacist and a certified trainer for the Covid-ID Lab test.
"Mr. Zdarek is an important addition to the Company, joining at the right time. With his technical experience as well as sales skills he will help expand our European distribution and sales networks," said Prof. Dr. Thomas Beckert. "Today's announcement is further to the recent appointments of Mr. Roland Spleiss as the Director of Business Development and Dr. Heinrich Jehle as the Head of Diagnostic Research. Strengthening the leadership is essential as the Company focuses resources on new product commercialization and sales growth of Covid-ID Lab and its novel oral biosensors."
Covid-ID Lab is a rapid RT-PCR test for the qualitative detection of SARS-CoV-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. To perform the test, Covid-ID Lab requires only a 20-minute PCR run time without prior RNA extraction as part of the sample preparation. The RT-PCR sample process detects the SARS-CoV-2 virus on a test chip within 5 minutes, when SARS-CoV-2 is present, the result can be read visually immediately. The target customers are airports, cruise lines, pharmacies, medical clinics, and any industrial or education site that requires rapid, definitive results.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
XPhyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Investor Inquiries:
Mr. Knox Henderson
T: 604-551-2360
E: info@xphyto.com
Forward looking statements
This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
SOURCE: XPhyto Therapeutics Corp.
View source version on accesswire.com:
https://www.accesswire.com/683669/XPhyto-Announces-Head-of-Sales-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Announces 2026 Strategic Objectives in Historically Strong PGE and Copper Markets13.1.2026 01:10:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / January 12, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU0(OTCQB:CLRMF) is pleased to provide an overview of its 2026 objectives and highlights of 2025, for its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Critical Project Advancement Objectives Spot prices for platinum, copper and palladium have appreciated by 70% (1000 $/oz), 25% (1.20 $/lb) and 50% 624($/oz) respectively versus study prices, since the results of the Preliminary Economic Assessment (PEA) were announced in the October 9th release. Using the financial model published in the PEA and applying current spot metal prices (as of January 6th), the TBN project shows a $708M1 NPV8 and a pre-tax IRR of 100% (post-tax NPV8 = $494M1 and IRR = 84%).This is a significant improvement in the project outlook in comparison to the PEA results that featured a $219.4M2 pre-tax NPV8 and a pre-tax IRR of 39%. This year, cons
Germany Buys Eight MQ-9B SeaGuardian(R) RPA Through NSPA12.1.2026 20:00:00 CET | Press release
NSPA Supports NATO Countries in the Acquisition and Sustainment of GA-ASI's Advanced Multi-Domain RPA SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 12, 2026 / Germany's Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support and the NATO Support and Procurement Agency (NSPA) have announced the procurement of eight MQ-9B SeaGuardian® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI). The program includes four Certifiable Ground Control Stations. First delivery is expected in 2028. Germany joins a growing list of NATO countries that have selected GA-ASI's advanced MQ-9B RPA for its multi-domain capabilities with exceptionally long range and endurance. The platform provides pole-to-pole satellite control and de-icing capabilities to enable missions in cold climates. SeaGuardian features two multi-mode surface-search radars that deliver wide-area maritime surveillance, with an option to add Anti-Submarine Warfare capa
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom